2022 World Conference on Lung Cancer (ePosters)-EP08.02-070. High Incidence of Peridiagnosis Thromboembolic Events In Patients with BRAF Mutant Lung Cancer

Pdf Summary

This document presents the results of a study conducted to determine the risk of thromboembolic events (TEE) in patients with non-small-cell lung cancer (NSCLC) harboring BRAF mutations. The study included 182 patients with BRAF-mutant NSCLC, with 48 patients (26.4%) experiencing TEE. The types of TEE observed included arterial and venous events, and some patients developed both types of events. The incidence rate of TEE in patients with BRAF-mutant NSCLC was found to be 26.4%.<br /><br />The study aimed to determine if BRAF-mutant NSCLC is associated with a higher risk of TEE, which could negatively impact patient survival. The results suggest that BRAF-mutant NSCLC may indeed be associated with a higher risk of TEE. If these findings are confirmed in larger prospective cohorts, prophylactic anticoagulation may be recommended for these patients.<br /><br />The study was conducted retrospectively, with patients identified from 18 participant centers in Spain between 2008 and 2021. The BRAF mutational status was determined in 82% of the patients using next-generation sequencing. Information on thromboembolic events, including the number of events, dates, treatments received, and survival, was assessed.<br /><br />The document includes figures showing the peridiagnosis cumulative incidence of TEE, the types of TEE observed, and the overall incidence rate of TEE in the study population. It also provides tables presenting the baseline clinical characteristics of the patients and their cancer treatment.<br /><br />In conclusion, the study found a high incidence of thromboembolic events in patients with BRAF-mutant lung cancer. These findings suggest that patients with BRAF-mutant NSCLC may be at a higher risk of TEE and may require prophylactic anticoagulation. Further research in larger prospective cohorts is needed to confirm these results.

Asset Subtitle

Inmaculada Aparicio Salcedo

Meta Tag

Speaker Inmaculada Aparicio Salcedo

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

thromboembolic events

risk assessment

non-small-cell lung cancer

BRAF mutations

arterial events

venous events

incidence rate

patient survival

prophylactic anticoagulation

retrospective study